Meeting
2016 ASCO Annual Meeting
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
Authors
Todd Michael Bauer
Sarah Cannon Research Institute, and Tennessee Oncology, PLLC., Nashville, TN
Todd Michael Bauer , Douglas Adkins , Gary K. Schwartz , Theresa Louise Werner , Ajjai Shivaram Alva , David S. Hong , Richard D. Carvajal , Mansoor N. Saleh , Lyudmila Bazhenova , Sanjay Goel , Keith D. Eaton , Robert D. Siegel , Ding Wang , Richard C. Lauer , Saskia T.C. Neuteboom , Demiana Faltaos , Isan Chen , James Christensen , Richard C. Chao , Rebecca Suk Heist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02219711
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2575)
DOI
10.1200/JCO.2016.34.15_suppl.2575
Abstract #
2575
Poster Bd #
275
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
First Author: Gary K. Schwartz
Poster
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
First Author: Christian K. Kollmannsberger
Poster
2019 ASCO Annual Meeting
A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.
First Author: Gary Edward Richardson
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan